Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PREDICTION-ADR

Financiado

Cerrado

Personalisation of tREatment In Cardiovascular disease through next generation s...

Personalisation of tREatment In Cardiovascular disease through next generation sequencing in Adverse Drug Reactions Prediction-ADR aims to discover the genetic factors predisposing patients to adverse drug reactions (ADRs) from cardiovascular disease (CVD) drugs. This will be achieved by assembling a consented blood bank and DNA for a populatio... ver más

28/02/2017

UNIVDUN

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

UNIVERSITY OF DUNDEE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-02-28 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

UNIVDUN

0.00€ | Lider

N.D. | Participante

THE UNIVERSITY OF LIVERPOOL

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PDC2021-121243-I00 PLATAFORMA DELFOS: SISTEMA DE INFORMACION PARA LA GESTION DE... 102K€ Cerrado

PharmGenHUB Pharmacogenomics Hub in a strengthened IMGGE 1M€ Cerrado

FIGHTINGDRUGFAILURE Priorities and Standards in Pharmacogenomic Research Opport... 3M€ Cerrado

GENOMICMEDICINE Towards evidence based genomic medicine filling the evidenc... 1M€ Cerrado

MLPM2012 Machine Learning for Personalized Medicine 4M€ Cerrado

Líder del proyecto

UNIVERSITY OF DUNDEE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Prediction-ADR aims to discover the genetic factors predisposing patients to adverse drug reactions (ADRs) from cardiovascular disease (CVD) drugs. This will be achieved by assembling a consented blood bank and DNA for a population of ~500 cases of ACEi induced angioedema and statin induced myopathy defined using a standardised phenotypic criteria. An innovative next generation sequencing strategy will be used to find predisposing genetic changes to myopathy and angioedema. Our SME partner will use proprietary software to build a highly predictive genetic algorithm for subsequent performance evaluation in real world clinical datasets involving >50,000 patients. This will deliver a novel set of genomic biomarkers to improve effective prevention or treatment of CVD providing the EU SME competitive advantage in the emerging personalised medicine market. The number of CVD drug prescriptions globally means that the absolute number of adverse drug reactions (ADRs) is substantial resulting in harm to the patients and leading to discontinuation and increased risk of CVD progression. Genome wide association studies (GWAS) has recently accelerated the progress in determining genetic biomarkers for adverse responses to drugs and with the advent of affordable whole genome sequencing, genetic research is now positioned to accelerating it even further. This provides a new opportunity to discover improved genomic biomarkers for extreme phenotypes of severe ADRs. The ultimate goal is to have these markers accepted by EMA and FDA and to disseminate these findings not only to the scientific community but also to lay people and patient organisations. This genetic algorithm will be developed into a commercially available clinical test by Asper Biotech. As 7 Million individuals were treated with statins in the UK alone during 2012, the size of the potential market for this test is immense.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores